#Tagrisso
#pharma #Imfinzi #Farxiga

🇬🇧 #$AZN AstraZeneca grew Q3 revenue 7% to $16.2bn. Sales of cancer medicines rose $927m (+15%), led by Imfinzi; Farxiga fell $529m (−25%) on US generics and China's volume-based procurement. Core EPS +17%; 2026 guidance held.

midgardfinance.com/companies/AZN.L/
October 30, 2026 at 8:25 AM
Patients with MET-altered advanced non-small cell lung cancer lived significantly longer with a targeted combination after progression on standard-of-care osimertinib (Tagrisso), a large randomized trial showed. #ESMO26
https://www.medpagetoday.com/meetingcoverage/esmo/123596
Targeted Doublet Improves Survival in MET-Positive Progressive Lung Cancer
PFS rises by 2 months, OS by 5 months with osimertinib-savolitinib after osimertinib progression
www.medpagetoday.com
October 27, 2026 at 9:47 PM
In phase 3 SANOVO, savolitinib + osimertinib (Tagrisso) extended median PFS to 24.9 months vs 13.8 months with osimertinib alone in the overall study population.
@myesmo.bsky.social #ESMO36 #lcsm

🔗 Read more: www.onclive.com/view/savolit...
October 27, 2026 at 12:45 AM
Tagrisso-Orpathys Combination Extends Survival in MET-Driven Lung Cancer Trial The Phase III SAFFRON trial showed longer progression-free and overall survival with...

https://www.narrowit.com/news/astrazeneca-tagrisso-orpathys-saffron-survival-2026-10-25
#Astrazeneca #HUTCHMED #Tagrisso #Orpathys
Tagrisso Plus Orpathys Improves Survival in SAFFRON Phase III Trial | Narrowit.com
AstraZeneca reported that Tagrisso plus Orpathys extended progression-free and overall survival in MET-driven EGFR-mutated lung cancer after Tagrisso.
www.narrowit.com
October 26, 2026 at 12:12 AM
The company submitted an application containing data from the SAFFRON trial, which was published in NEJM and presented at the ESMO Congress.
AstraZeneca Pursuing FDA Approval for EGFR-MET Combo in Tagrisso-Resistant NSCLC Patients
AstraZeneca Pursuing FDA Approval for EGFR-MET Combo in Tagrisso-Resistant NSCLC Patients
ebx.sh
October 26, 2026 at 3:32 AM
#$AZN TAGRISSO + Savolitinib delivers strong Phase 3 data in lung cancer.

- 45% reduction in risk of disease progression or death
- 32% reduction in risk of death
- Targets MET-driven, EGFR-mutated patients who progressed on prior TAGRISSO
October 25, 2026 at 7:13 PM
Researchers found that ctDNA analysis can provide indication of early progression for Lorbrena, while the biomarker did not show to be clearly useful for selecting patients for Tagrisso.
Experts at ESMO Unsure if ctDNA Should Alter Intensification Strategy With NSCLC Targeted Therapy
Experts at ESMO Unsure if ctDNA Should Alter Intensification Strategy With NSCLC Targeted Therapy
ebx.sh
October 25, 2026 at 4:33 PM
vilket behandlas med sk TKI-cancerläkemedel som Azn:s Tagrisso (försäljning 7 busd av Azn:s totala försäljning 59 busd 2025)

TKI =Tyrosine Kinase Inhibitor, "tyrosinkinas? Det är en typ av enzym (protein) inuti kroppens celler som fungerar som en strömbrytare" enl Google
October 8, 2026 at 8:54 AM
AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination reut.rs/3VkeKiC
AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination
HUTCHMED (China) said on Tuesday ​that Anglo-Swedish drugmaker AstraZeneca ‌had applied to the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO ​combination to treat patients with advanced ​lung cancer.
reut.rs
September 29, 2026 at 5:25 AM
AstraZeneca & HUTCHMED submitted a US NDA for all-oral ORPATHYS + TAGRISSO in EGFRm NSCLC with MET overexpression/amplification post-EGFR-TKI. Phase III SAFFRON trial reported improved survival vs chemotherapy; detailed results follow at ESMO 2026. Filing acceptance pending. #Pharma
September 29, 2026 at 7:07 AM
AstraZeneca & HUTCHMED submitted a US NDA for all-oral ORPATHYS + TAGRISSO in EGFRm NSCLC with MET overexpression/amplification post-EGFR-TKI. Phase III SAFFRON trial reported improved survival vs chemotherapy; detailed results follow at ESMO 2026. Filing acceptance pending.
September 29, 2026 at 6:52 AM
Cancer Grand Challenges, through the Torrey Coast Foundation and Cancer Research UK, commits up to $34M to gastroesophageal cancer research
https://cancerletter.com/funding-opportunities/20260925_8a/
Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds - The Cancer Letter
Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared
cancerletter.com
September 28, 2026 at 10:00 PM
Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds
https://cancerletter.com/clinical-roundup/20260925_9a/
FDA approves Lyrfigtu for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma - The Cancer Letter
FDA granted approval for Lyrfigtu (lirafugratinib) as a treatment option for patients with cholangiocarcinoma with FGFR2
cancerletter.com
September 28, 2026 at 12:00 PM
"His particular lung cancer mutation, EGFR, has a targeted prescription medicine – osimertinib, with the brand name of Tagrisso – that blocks a protein that causes cancer cells to grow and multiply."
Pistons EVP of basketball ops Michael Blackstone has stage 4 lung cancer, despite being a nonsmoker.

“If I didn’t pay attention to the discomfort that I was having and asked a very innocent question, I wouldn't be here right now. That’s the truth."
www.freep.com/story/sports...
Pistons' Michael Blackstone has cancer, but it's not end of his story
For Pistons' Michael Blackstone, a stage 4 lung cancer diagnosis started with pain in his right shoulder. He wants people to learn from his situation.
www.freep.com
September 22, 2026 at 2:52 AM
More encouraging lung cancer research. Tagrisso plus Orpathys significantly improved progression-free survival in a Phase 3 trial for patients with advanced EGFR-mutated lung cancer and MET overexpression.

www.astrazeneca.com/media-centre...

#LungCancer #CancerResearch #TCSC
Tagrisso plus Orpathys demonstrated statistically significant and highly clinically meaningful improvement in progression-free survival in 1st-line MET-overexpressing EGFR-mutated lung cancer
www.astrazeneca.com
September 14, 2026 at 7:53 AM
Long-term survival continues to improve for some people with EGFR-mutated lung cancer. Tagrisso has produced encouraging long-term survival results following surgery for early-stage disease.

www.astrazeneca.com/media-centre...

#LungCancer #CancerTreatment #TCSC
Tagrisso achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial
www.astrazeneca.com
September 14, 2026 at 7:51 AM
Tagrisso combo succeeds in first-line MET-overexpressing lung cancer study
#$AZN firstwordpharma.com/story/7936422
September 1, 2026 at 10:12 PM
AstraZeneca's Tagrisso-Orpathys combo hits goal in first-line lung cancer trial
AstraZeneca's Tagrisso-Orpathys combo hits goal in first-line lung cancer trial
The Phase III SANOVO trial showed Tagrisso plus Orpathys significantly improved progression-free survival in treatment-naïve, MET-overexpressing EGFR-mutated lung cancer patients, extending the combination's reach into first-line treatment.
dlvr.it
September 1, 2026 at 6:44 AM
🚨 #BREAKING : ASTRAZENECA PLC - TAGRISSO + ORPATHYS IMPROVED PFS IN 1L EGFRM LUNG, AS PER REUTERS
X
September 1, 2026 at 6:00 AM